These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 24594636)

  • 1. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
    Gelao L; Criscitiello C; Esposito A; Goldhirsch A; Curigliano G
    Toxins (Basel); 2014 Mar; 6(3):914-33. PubMed ID: 24594636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supportive care for patients undergoing immunotherapy.
    Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
    Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
    Kottschade LA
    Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The pathology of adverse events with immune checkpoint inhibitors].
    Koelzer VH; Glatz K; Bubendorf L; Weber A; Gaspert A; Cathomas G; Lugli A; Zippelius A; Kempf W; Mertz KD
    Pathologe; 2017 May; 38(3):197-208. PubMed ID: 28421272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy-related adverse events: causes and challenges.
    Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
    Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionally Masked Antibody to Uncouple Immune-Related Toxicities in Checkpoint Blockade Cancer Therapy.
    Song SH; Ghosh T; You DG; Joo H; Lee J; Lee J; Kim CH; Jeon J; Shin S; Park JH
    ACS Nano; 2023 Jun; 17(11):10065-10077. PubMed ID: 37184643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
    Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
    Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
    Ma W; Gilligan BM; Yuan J; Li T
    J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing Immune-Related Adverse Events in Cancer Immunotherapy.
    Farmer JR
    Clin Lab Med; 2019 Dec; 39(4):669-683. PubMed ID: 31668277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of cancer immunotherapy toxicity.
    Kennedy LB; Salama AKS
    CA Cancer J Clin; 2020 Mar; 70(2):86-104. PubMed ID: 31944278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
    Champiat S; Lambotte O; Barreau E; Belkhir R; Berdelou A; Carbonnel F; Cauquil C; Chanson P; Collins M; Durrbach A; Ederhy S; Feuillet S; François H; Lazarovici J; Le Pavec J; De Martin E; Mateus C; Michot JM; Samuel D; Soria JC; Robert C; Eggermont A; Marabelle A
    Ann Oncol; 2016 Apr; 27(4):559-74. PubMed ID: 26715621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding adverse events of immunotherapy: A mechanistic perspective.
    Burke KP; Grebinoski S; Sharpe AH; Vignali DAA
    J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33601411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivering safer immunotherapies for cancer.
    Milling L; Zhang Y; Irvine DJ
    Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gastrointestinal complications of the new immune checkpoint inhibitor therapies].
    Götze J; Bitzer M; Malek NP
    Dtsch Med Wochenschr; 2019 Dec; 144(24):1731-1736. PubMed ID: 31791080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity.
    Kuchroo JR; Hafler DA; Sharpe AH; Lucca LE
    Sci Immunol; 2021 Nov; 6(65):eabf4034. PubMed ID: 34739340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.